|
| Friday, November 15, 2019 |
|
|
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats |
| Global BioLife Inc, the U.S.subsidiary of SGX-listed Singapore eDevelopment Ltd (SeD), will present research on its 3F Antimicrobial Fragrance as a new method to prevent and treat Tuberculosis at the 2020 ASM Biothreats conference, taking place from 28 to 30 January 2020 in Arlington, Virginia. more info >> |
|
| Tuesday, October 29, 2019 |
|
|
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis |
| SGX-listed Singapore eDevelopment Limited ("SeD", SGX:40V) wishes to announce that its biomedical subsidiary incorporated in Nevada, Global BioLife Inc. ("Global BioLife") will be presenting its research on its Functional Fragrance Formula ("3F") against tuberculosis at the 2020 American Society for Microbiology ("ASM") Biothreats Conference. more info >> |
|
| Wednesday, July 24, 2019 |
|
|
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit |
| SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce the results of clinical trials conducted on Laetose(TM), developed by its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife"). more info >> |
|
| Wednesday, June 12, 2019 |
|
|
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing |
| SGX-listed Singapore eDevelopment Ltd (SeD) wishes to announce that its U.S. biomedical subsidiary Global BioLife Inc. has independently tested its new 3F Mosquito Formula which performs well against mosquitoes for six (6) to eight (8) hours. more info >> |
|
| Monday, January 28, 2019 |
|
|
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis |
| SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis. more info >> |
|
| Wednesday, November 7, 2018 |
|
|
Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018 |
| Singapore eDevelopment (SGX: 40V) ("SeD") subsidiary, Global BioLife Inc. is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California. more info >> |
|
| Monday, June 18, 2018 |
|
|
Singapore eDevelopment Limited Announces Corporate and Business Update |
| The Board of Directors of Singapore eDevelopment Limited wishes to provide shareholders an update on the Group's operations. more info >> |
|
| Thursday, May 31, 2018 |
|
|
Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar |
| Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. ("Global BioLife"), has developed a low glycemic index, naturally modified sugar - Laetose - which has the potential to affect the world's sugar market. more info >> |
|
| Thursday, March 1, 2018 |
|
|
Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola |
| Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker. more info >> |
|
| Wednesday, November 1, 2017 |
|
|
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance |
| SGX-listed Singapore eDevelopment Ltd (SeD) announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric. more info >> |
|
|
|
|
